Tyme Technologies, Inc. and the Joseph Ahmed Foundation Announce Planned Trial for SM-88 in Ewing’s Sarcoma
September 27, 2018 08:00 ET
|
Tyme Technologies, Inc.
Recognized sarcoma thought leader, Dr. Sant P. Chawla, will conduct the investigator-initiated Phase II studyThe Joseph Ahmed Foundation (“JAF”) will provide funding and patient support for the study...
Tyme Appoints Accomplished Healthcare Executive Douglas A. Michels to Board of Directors
September 18, 2018 08:00 ET
|
Tyme Technologies, Inc.
Former OraSure Technologies President and CEO and Johnson and Johnson executive to join Tyme board of directors James Biehl appointed as Chief Legal Officer of Tyme; to step down from the board of...
Tyme Exceeds Enrollment Expectations for the Phase II Trial of SM-88 in Pancreatic Cancer
September 05, 2018 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), today announced that the number of currently consented or randomized subjects has exceeded the enrollment target...
Tyme Technologies, Inc. to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
August 27, 2018 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will...
Tyme Technologies Provides Clinical and Corporate Update for Fiscal 1Q 2019
July 30, 2018 07:30 ET
|
Tyme Technologies, Inc.
NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical...
Tyme Technologies, Inc. Set to Join Russell 3000® Index
June 25, 2018 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced it is set to...
Tyme Releases Detailed Data and Analyses with SM-88 From the First Human Study and Compassionate Use Programs
June 12, 2018 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, June 12, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today release detailed patient data and...
Tyme Appoints Pharma Executive Don DeGolyer to Board of Directors
May 30, 2018 07:30 ET
|
Tyme Technologies, Inc.
NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Tyme, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced the appointment of Don DeGolyer to the...
Tyme Announces Five Clinical Abstracts at the 2018 ASCO Annual Meeting
May 17, 2018 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- Tyme, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced the availability of...
Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018
April 09, 2018 07:00 ET
|
Tyme Technologies, Inc.
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical...